A model made using machine learning can predict if CPAP use in patients with obstructive sleep apnea will benefit or harm ...

This one is for investors seeking quality, global reach, and durable earnings. The post 3 reasons to buy this $42 billion ASX ...

Noctrix Health developed and manufactures a novel non-invasive, wearable therapy to treat drug-refractory Restless Leg ...

Sleep apnoea company Resmed has acquired a California firm that makes a device for patients with restless leg syndrome, the ...

Featuring automotive-grade LiFePO4 (lithium iron phosphate) cells with 3,000+ charge cycles, precise digital battery ...

Earlier this week, ResMed (NYSE:RMD) reported that it will release its quarterly earnings on Thursday afternoon, with Wall Street expecting around 10% year-on-year revenue growth and earnings of about ...

CPAP machines are gaining popularity due to increased public discussion and awareness of sleep apnea. Affordable at-home sleep tests are now available, making diagnosis more accessible than ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

ResMed (NYSE: RMD) finds itself in an investment limbo as revolutionary weight loss drugs create both immediate opportunities and long-term existential questions for the sleep apnea device maker.

Every night, millions of people stop breathing without knowing it. Not once, but sometimes hundreds of times. Their remedy? A mask, a hum and the steady whisper of pressurised air. It’s not glamorous, ...